Skip to content
10-Q

Quarterly Report

SAB Biotherapeutics, Inc. SABS SABSW

0001193125-26-218195

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 76.46M sh
Shares Diluted Q1 2026 · Mar 31, 2026 53.56M sh
Shares Diluted Q1 2026 · Mar 31, 2025 9.29M sh
Capex Q1 2026 · Mar 31, 2026 $983.26K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.27M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.8M
Short Term Investments Q1 2026 · Mar 31, 2026 $86.87M
Short Term Investments Q1 2026 · Dec 31, 2025 $86.09M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $20.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $10.5M
Stockholders Equity Q1 2026 · Mar 31, 2026 $227.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 $151.49M
Stockholders Equity Q1 2026 · Mar 31, 2025 $21.41M
Stockholders Equity Q1 2026 · Dec 31, 2024 $25.97M
Current Liabilities Q1 2026 · Mar 31, 2026 $9.85M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.68M
Total Liabilities Q1 2026 · Mar 31, 2026 $21.22M
Total Liabilities Q1 2026 · Dec 31, 2025 $21.32M
Current Assets Q1 2026 · Mar 31, 2026 $112.78M
Current Assets Q1 2026 · Dec 31, 2025 $101.05M
Total Assets Q1 2026 · Mar 31, 2026 $248.47M
Total Assets Q1 2026 · Dec 31, 2025 $172.81M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.35
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.56
Eps Basic Q1 2026 · Mar 31, 2026 −$0.35
Eps Basic Q1 2026 · Mar 31, 2025 −$0.56
Sga Expense Q1 2026 · Mar 31, 2026 $6.6M
Sga Expense Q1 2026 · Mar 31, 2025 $3.11M
Rd Expense Q1 2026 · Mar 31, 2026 $13.4M
Rd Expense Q1 2026 · Mar 31, 2025 $7.66M
Net Income Q1 2026 · Mar 31, 2026 −$18.87M
Net Income Q1 2026 · Mar 31, 2025 −$5.2M
Operating Income Q1 2026 · Mar 31, 2026 −$20M
Operating Income Q1 2026 · Mar 31, 2025 −$10.77M